Searchable abstracts of presentations at key conferences in endocrinology

ea0081p661 | Pituitary and Neuroendocrinology | ECE2022

Metyrapone vs osilodrostat in the short-term therapy of endogenous Cushing’s syndrome: results from a retrospective single center analysis

Detomas Mario , Altieri Barbara , Deutschbein Timo , Fassnacht Martin , Dischinger Ulrich

Background: Although surgery is considered the first-line treatment for patients with endogenous Cushing’s syndrome (CS), medical therapy is often required to control severe hypercortisolism. Metyrapone and osilodrostat are inhibitors of 11β-hydroxylase that have not been directly compared yet.Methods: Retrospective analysis of patients with adrenocorticotropin (ACTH)-dependent and ACTH-independent CS treated with metyrapone or osilodrostat (as...

ea0090ep41 | Adrenal and Cardiovascular Endocrinology | ECE2023

The role of CRH test in predicting the efficacy of unilateral adrenalectomy in Bilateral Macronodular Adrenal Hyperplasia

Tizianel Irene , Detomas Mario , Deutschbein Timo , Carla Scaroni , Ceccato Filippo

Background and Aim: Bilateral Macronodular Adrenal Hyperplasia (BMAH) is a rare form of adrenal Cushing’s syndrome (CS). The treatment of choice in patients with BMAH and overt CS is bilateral adrenalectomy (B-Adx), which however implies lifelong glucocorticoid and mineralocorticoid replacement therapy. Unilateral adrenalectomy (U-Adx) has been proposed as an alternative to B-Adx, especially in case of clearly asymmetric adrenal size. Our aim was to determine predictive f...

ea0073aep826 | Late Breaking | ECE2021

The promising role of Agouti related peptide in the differentiation of ACTH-independent Cushing syndrome

Detomas Mario , Altieri Barbara , Fassnacht Martin , Dischinger Ulrich

BackgroundAgouti related peptide (AgRP) is a neuropeptide, produced by the hypothalamus and by the adrenal glands. AgRP is an antagonist of proopiomelanocortin (POMC) and its principal role is to stimulate appetite. Although current evidences suggest that AgRP levels are influenced by glucocorticoids, it is still not clear, whether they depend on adrenocorticotropic hormone (ACTH) or cortisol. One of the aims of this study was to address this issue. Furt...

ea0090oc9.4 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma

Altieri Barbara , Kimpel Otilia , Megerle Felix , Detomas Mario , Chifu Irina , Quinkler Marcus , Matthias Kroiss , Fassnacht Martin

Background: Mitotane is regularly used in patients with adrenocortical carcinoma (ACC) adjuvantly, in patients with high risk of recurrence, and in advanced disease. Multiple effects of mitotane result in adrenal insufficiency in virtually all patients. However, it is unclear how frequently the hypothalamic-pituitary-adrenal (HPA) axis is recovering after treatment discontinuation. Here, we aim to investigate the HPA axis after treatment with mitotane.Me...

ea0081p153 | Pituitary and Neuroendocrinology | ECE2022

Subtype-specific pattern of white blood cell differential in endogenous Cushing’s syndrome

Detomas Mario , Altieri Barbara , Chifu Irina , Remde Hanna , Landwehr Laura-Sophie , Sbiera Silviu , Kroiss Matthias , Fassnacht Martin , Deutschbein Timo

Objective: Glucocorticoid excess impairs immune function, thereby predisposing patients with endogenous Cushing’s syndrome (CS) to infections. However, it is still not clear whether there is a CS-subtype specific pattern in white blood cell (WBC) and WBC differential (WBCD) count.Methods: Retrospective monocentric cohort study in patients with either overt endogenous CS or adrenal adenomas with autonomous cortisol secretion (ACS), with WBC and WBCD ...

ea0086p9 | Adrenal and Cardiovascular | SFEBES2022

Inflammation-Based Scores as Predictors of Treatment Response in Advanced Adrenocortical Carcinoma

Mangone Alessandra , S. Elhassan Yasir , Prete Alessandro , Asia Miriam , Detomas Mario , Altieri Barbara , Mantovani Giovanna , Ronchi Cristina L.

Background: Standard treatment for advanced adrenocortical carcinoma (ACC) is mitotane in monotherapy or combined with etoposide, doxorubicin and cisplatin (EDP), yet biomarkers predictive of treatment response are lacking. Inflammation-based scores were proposed as predictors for gemcitabine+capecitabine efficacy, used as second-line in progressive ACC. We investigated the role of inflammation-based scores in predicting response to first-line treatment in advanced ACC.<p ...

ea0090p275 | Adrenal and Cardiovascular Endocrinology | ECE2023

Can Inflammation-Based Scores Help Predict Treatment Response in Advanced Adrenocortical Carcinoma?

Mangone Alessandra , Altieri Barbara , Detomas Mario , Prete Alessandro , Abbas Haider , Felicitas Asia Miriam , Elhassan Yasir , Mantovani Giovanna , Ronchi Cristina

Background: Treatment for advanced adrenocortical carcinoma (ACC) consists of mitotane alone or combined with etoposide, doxorubicin and cisplatin (EDP), yet their efficacy is limited and burdened with significant toxicity. Moreover, markers of response are lacking. Inflammation-based scores have been proposed as prognostic factors in several malignancies including ACC, and recently also as predictors of gemcitabine+capecitabine efficacy, second-line treatment in progressive d...

ea0090p681 | Pituitary and Neuroendocrinology | ECE2023

Erythropoiesis in endogenous Cushing syndrome: sex-related and subtype-specific differences

Detomas Mario , Deutschbein Timo , Tamburello Mariangela , Chifu Irina , Kimpel Otilia , Sbiera Silviu , Kroisz Matthias , Fassnacht Martin , Altieri Barbara

Context: Endogenous Cushing syndrome (CS) is associated with hematological abnormalities. Nevertheless, conflicting data have been reported on erythropoiesis. Some studies reported an association between CS and anemia in men, whereas others described erythrocytosis in affected patients. Furthermore, it is unclear whether there are CS subtype-specific changes in red blood cells (RBC) parameters.Objective: To investigate sex and subtype-specific changes in...

ea0081rc4.7 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

The burden of pain in patients with acromegaly

Kreitschmann-Andermahr Ilonka , Kahl Annalena , Deutschbein Timo , Honegger Jurgen , Unger Nicole , Detomas Mario , Giese Sabrina , Schroeder Bernadette , Chmielewski Witold , Siegel Sonja

Introduction: The aim of the present study was to explore pain prevalence, pain locations and its impact on everyday activities and health-related quality of life (QoL) in a large cohort of patients with acromegaly.Methods: We conducted a survey at three major centers specialized on the treatment of pituitary diseases. 124 patients with acromegaly (mean age 56.6y ± 13.5) filled in a self-constructed questionnaire on acromegaly symptoms, pain includi...

ea0073aep838 | Late Breaking | ECE2021

Consecutive development of adrenal Cushing´s syndrome and Cushing´s disease in a female patient with somatic CTNNB1, USP8, and NR3C1 mutations

Detomas Mario , Altieri Barbara , Schlötelburg Wiebke , Appenzeller Silke , Sven-Martin Schlaffer , Roland Coras , Andreas Schirbel , Wild Vanessa , Kroiss Matthias , Sbiera Silviu , Fassnacht Martin , Deutschbein Timo

ContextThe occurrence of different subtypes of endogenous Cushing’s syndrome (CS) in single individuals is extremely rare. We here present the case of a female patient who was successfully cured from adrenal CS 4 years before being diagnosed with Cushing’s disease (CD).Case DescriptionA 50-year-old female was diagnosed with ACTH-independent CS and a left-sided adrenal adenoma in January 2015. After ...